Revolution Medicines Insider Sells $3.15M in Planned 10b5-1 Trade

Executive Summary

On September 10, 2026, Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc. ($RVMD), executed a series of open-market stock sales totaling 15,448 shares for aggregate gross proceeds of approximately $3.15 million. The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on June 11, 2026.

Transaction Details

• Option Exercise: Mancini exercised 9,363 stock options with an exercise price of $33.62 per share.
• Sales: Mancini sold 15,448 common shares across multiple price tranches ranging from $202.64 to $207.28, at a weighted average price of approximately $204.16 per share.
• Post-Transaction Holdings: Following these transactions, Mancini directly owns 43,890 shares of common stock (which includes 43,700 restricted stock units) and retains 96,746 derivative stock options.

Market & Strategic Context

The trades were executed strictly pursuant to a pre-scheduled Rule 10b5-1 plan established months in advance. Because the activity represents planned programmatic option exercises and portfolio diversification rather than discretionary market timing, market significance is deemed Low.